Oxidation of the actin cytoskeleton regulator cofilin-1 as a mediator of endothelial stiffening and dysfunction in type 2 diabetes
Authors: Power Gavin , Gonazalez-Vallejo Juan D. , Lateef Olubodun M. , Augenreich Marc A. , Lazo-Fernandez Yoskaly , Ramirez-Perez Francisco I. , Manrique-Acevedo Camila 
Published: May 2024

Vascular disease is a feature of type 2 diabetes (T2D) that is caused in part by oxidative stress and endothelial dysfunction. An emerging instigator of endothelial dysfunction is stiffening of the cell, which is mediated by enhanced polymerization of filamentous actin (F-actin). Actin polymerization is regulated by cofilin-1, an actin severing protein that can be phosphorylated or oxidized, leading to its inactivation and loss of severing capability. Yet, the mechanisms contributing to endothelial stiffening in T2D remain largely unknown. Herein, we tested the hypothesis that endothelial stiffening in T2D is mediated by inactivation of cofilin-1, leading to actin polymerization. In support of this hypothesis, human umbilical vein endothelial cells (HUVECs) treated with plasma from subjects with T2D, and the aortic endothelium of diabetic mice (db/db), demonstrate increased cellular stiffness and F-actin presence. Of note, these findings were not associated with enhanced phosphorylation of cofilin-1, suggesting that its inactivation may instead occur through oxidation. Indeed, we show that cofilin-1 can be oxidized by H2O2, a strong oxidizing agent, and that exposure of HUVECs to H2O2 induces F-actin formation. These findings implicate oxidation and inactivation of cofilin-1 as a putative driver of endothelial F-actin formation and cellular stiffening. In further support of the notion that inactivation of cofilin-1 in endothelial cells promotes cytoskeletal remodeling, we show that genetic silencing or pharmacological inhibition of LIM kinase-1 (LIMK-1), a key enzyme responsible for phosphorylating and thus inactivating cofilin-1, reduces F-actin content and cellular stiffness. Congruently, we show that LIMK inhibition reduces endothelial stiffness in aortic explants from db/db mice. It is conceivable that increased endothelial actin polymerization and stiffening impact vasomotor function. As proof-of-concept, we show that intraluminal exposure of isolated arteries to jasplakinolide, a pharmacological inducer of actin polymerization, impairs endothelial-dependent vasodilation, as assessed via flow-mediated dilation (FMD), while endothelium-independent vasodilation remains unaffected. Conversely, cytochalasin D, an inhibitor of actin polymerization, improves FMD, without influencing endothelium-independent vasodilation. Taken together, these findings suggest the existence of a potential new paradigm of T2D-associated endothelial dysfunction whereby oxidative stress inactivates cofilin-1, contributing to F-actin-dependent endothelial stiffening. Moreover, this work supports the idea that LIMK-1 may be considered a potential target for reducing cofilin-1 inactivation and reversing endothelial stiffening in T2D. Funding: R01HL151384, R01HL153264, R01HL137769, and AHA23PRE1020897. This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.